
    
      Scheme:

      Eligible stage II and III NPC patients will first be stratified by institution, then
      randomized to 2 arms at 1:1 ratio.

      - Arm Cisplatin: cisplatin 40mg/m2/week in concurrent with IMRT

      - Arm nimotuzumab: nimotuzumab 200mg/week in concurrent with IMRT
    
  